Multiple system atrophy: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SNCA 1
• LRRK2 0
• TDP-43 0
• BDNF 0
• CSF1R 0
• mTOR 0
• NLRP3 0
• PI3K 0
• TNF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · R01

  Persistent organic pollutants in prodromal Lewy Body Dementia: An exposomic investigation of neurotoxic exposures and clinical disease progression

  Barrow Neurological Institute at St. Joseph's Hospital and Medical Center· Phoenix, United States· US$657,088 awarded in fiscal year 2026· until Aug 2031

• NIH NIA · R01

  Role of the microbiome in modulating immune-mediated amyloid clearance in Alzheimer's disease

  Brigham and Women's Hospital· Boston, United States· US$709,149 awarded in fiscal year 2026· until May 2031

• NIH NINDS · RF1

  Interrogating alpha-synuclein aggregate-associated proteomes to identify modifiers of Lewy body disease.

  Mayo Clinic Jacksonville· Jacksonville, United States· US$1,878,189 awarded in fiscal year 2026· until Aug 2029

• NIH NINDS · R01

  Effect of fibril structure on the disease pathogenesis of a novel alpha-synuclein strain

  Colorado State University· Fort Collins, United States· US$635,317 awarded in fiscal year 2026· until May 2031

• NIH NINDS · R01

  Integrated MRI Biomarkers of Atrophy and Iron Dysregulation in Multiple System Atrophy

  Vanderbilt University Medical Center· Nashville, United States· US$444,336 awarded in fiscal year 2026· until May 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechanism-driven neuroprosthetics to restore hemodynamic stability in parkinsonian syndromes (HemoPARK)

  Centre Hospitalier Universitaire Vaudois· Lausanne, Switzerland· EU contribution €1,500,000· until Feb 2031

  The disease is named only in the funder's project summary, not in the title.

6 of 50 running projects, newest first. Listed amounts together: US$38.8m + €1.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Gene Expression Profiling 1
• Whole Genome Sequencing 3
• Exome Sequencing 1
• Proteomics 1
• Metabolomics 4
• Mass Spectrometry 1
• Immunohistochemistry 2
• Positron-Emission Tomography 21
• Magnetic Resonance Imaging 39
• Machine Learning 10
• Deep Learning 3
• Cohort Studies 10
• Genome-Wide Association Study 2

• The protocol for a phase 2A, multi centre, double-blind, randomized, placebo-controlled, parallel-group study to assess the effect of 12 weeks treatment with oral PXS-4728A on microglia activation, as measured by positron emission tomography, in participants with isolated rapid eye movement sleep behaviour disorder.

  Front Neurol, Oct 2026

• Synaptic vesicle glycoprotein 2A PET imaging in parkinsonian α-synucleinopathies: a systematic review.

  J Neurol, Sept 2026

• Peripheral and central inflammation in progressive supranuclear palsy syndrome: an immunological and imaging neuroinflammation study.

  Front Immunol, Jul 2026

• Caudate-Predominant Striatal Dopaminergic Deficit Distinguishes Behavioral Variant of Frontotemporal Dementia With Parkinsonism From Other Parkinsonian Syndromes.

  Clin Nucl Med, Jul 2026

• Beyond Parkinson's: The Challenge of Diagnosing Multiple System Atrophy-C.

  Ann Afr Med, Jun 2026

• Coexisting Amyloid Positivity and Probable Dementia With Lewy Bodies in a Patient With Rapid Eye Movement Sleep Behavior Disorder.

  Am J Case Rep, Jun 2026

• FDG-PET in Movement Disorders and Parkinsonian Syndromes.

  PET Clin, Jun 2026

• Cerebral metabolic trajectories alterations in multiple system atrophy: A longitudinal FDG-PET study.

  J Parkinsons Dis, May 2026

• Feasibility of short imaging protocols for [18F]fluordeprenyl-D2 PET in autoimmune encephalitis and multiple system atrophy.

  Eur J Nucl Med Mol Imaging, May 2026

• The PET tracer [11C]MODAG-005 targets alpha-synuclein aggregates in the brain.

  Sci Transl Med, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.